Search AI Products and News

Just weeks after OpenAI announced its adoption of a rival Anthropic standard for connecting AI models to the systems where their data resides, Google has followed suit. Google DeepMind CEO Demis Hassabis announced on X on Wednesday that Google will add support for the Anthropic Model Context Protocol (MCP) to its Gemini models and software development kits (SDKs).

In the fiercely competitive AI industry, Google's AI division, DeepMind, has employed extreme measures to retain top talent. According to Business Insider, some of the company's AI employees in the UK have signed 'aggressive' non-compete agreements, preventing them from working for competitors for a year after leaving. These agreements not only restrict employees' career choices but also prevent them from participating in the rapidly advancing technologies within the industry for a full year. Reports indicate these employees continue to receive salaries during this period, though the specifics are unclear.

Google DeepMind recently released a comprehensive strategic document outlining its approach to developing safe Artificial General Intelligence (AGI). AGI is defined as a system capable of matching or exceeding human capabilities in most cognitive tasks. DeepMind anticipates that current machine learning approaches, particularly neural networks, will remain the primary path to achieving AGI. The report notes that future AGI systems could potentially surpass human performance and exhibit significant autonomy in planning and decision-making. This technology will have implications for healthcare...

Isomorphic Labs, a platform focused on AI-powered drug discovery, founded in 2021 as a spin-off from Google's DeepMind, has secured $600 million in Series A funding led by Thrive Capital, with participation from GV and existing investor Alphabet (Google's parent company). This funding will accelerate the further development of Isomorphic's AI drug design engine and support the company's R&D efforts.

Google recently announced the launch of its new open-source model, TxGemma, designed to significantly improve the efficiency of therapeutic drug development. Developed by the Google DeepMind team, this model is a fine-tuned version of their advanced Gemma model family, incorporating powerful natural language understanding, scientific prediction, and multi-turn dialogue capabilities. TxGemma aims to revolutionize drug discovery. Its release is considered a significant advancement in the application of AI to biomedicine, promising to drastically shorten the time it takes for drugs to move from the lab to clinical trials, while also reducing costs.

Google DeepMind has revealed its secret weapon – Gemini Robotics! This is no ordinary roomba; it's about truly infusing AI intelligence into robotic bodies, enabling robots to operate (and potentially even more cleverly) in the physical world, just like humans. The versatile Gemini Robotics is powered by the advanced Gemini 2.0 model. Gemini itself boasts the ability to process text, images, audio, and video.

At the recent 'Invest Karnataka 2025' conference held in Bangalore, numerous leaders from the technology industry gathered to discuss the transformative potential of artificial intelligence in India and its impacts. Manish Gupta, Senior Director at Google DeepMind, delivered a key speech at the conference, emphasizing the need to establish corresponding regulations alongside technological innovation to ensure responsible development. Note: Image generated by AI, image courtesy service provider Midjourney.

Recently, former DeepMind scientist Simon Kohl announced the establishment of a new artificial intelligence drug discovery company, aiming to leverage his extensive experience in protein prediction, particularly related to the Nobel Prize-winning AlphaFold system. AlphaFold is a revolutionary AI tool that can accurately predict the three-dimensional structure of proteins, a breakthrough that has garnered significant attention in biomedical research. Image source note: Image generated by AI, image licensed service.

Recently, an AI system developed by Google DeepMind—AlphaGeometry2—has successfully surpassed the average level of gold medalists at the International Mathematics Olympiad (IMO), demonstrating outstanding performance in solving geometry problems. AlphaGeometry2 is an upgraded version of the AlphaGeometry system released by DeepMind last year. According to the latest research from the research team, this system can solve 84% of the geometry problems from the IMO over the past 25 years.

At the recent World Economic Forum in Davos, Google DeepMind's CEO Demis Hassabis stated that the first drugs designed with the help of artificial intelligence could begin clinical trials by 2025. Hassabis also heads Isomorphic Labs, a drug research company under DeepMind. He stated, "Our plan is to have some AI-designed drugs enter clinical trials by the end of this year."

In multimodal tasks, visual language models (VLMs) play a crucial role, such as in image retrieval, image captioning, and medical diagnosis. These models aim to align visual data with language data for more efficient information processing. However, current VLMs still face significant challenges in understanding negation. Negation is critical in many applications, such as distinguishing between "a room without windows" and "a room with windows." Despite significant progress made by VLMs, existing models fall short when it comes to handling negated statements.